Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1 Lupus Erythematosus, Systemic 1 Infections 1

Interventions

pembrolizumab 302 Carboplatin 230 Cisplatin 159 Paclitaxel 153 Gemcitabine 153 Pemetrexed 122 Bevacizumab 121 Docetaxel 105 durvalumab 83 Oxaliplatin 82 Nivolumab 82 Dexamethasone 80 atezolizumab 79 Fluorouracil 79 Cyclophosphamide 79 130-nm albumin-bound paclitaxel 74 Fulvestrant 72 Capecitabine 67 Injections 66 Cetuximab 64 Leucovorin 63 Rituximab 57 fludarabine 52 Lenalidomide 51 venetoclax 47 Prednisone 45 Irinotecan 42 enzalutamide 41 Letrozole 41 tislelizumab 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × anifrolumab × 90 days × Clear all

NCT07000110 2026-05-20

SIMA

AstraZeneca

Infections, Lupus Erythematosus, Systemic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡